CY1121049T1 - Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων - Google Patents
Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνωνInfo
- Publication number
- CY1121049T1 CY1121049T1 CY181100941T CY181100941T CY1121049T1 CY 1121049 T1 CY1121049 T1 CY 1121049T1 CY 181100941 T CY181100941 T CY 181100941T CY 181100941 T CY181100941 T CY 181100941T CY 1121049 T1 CY1121049 T1 CY 1121049T1
- Authority
- CY
- Cyprus
- Prior art keywords
- signal sequences
- bip
- heavy chain
- binding protein
- disclosed
- Prior art date
Links
- 108010076504 Protein Sorting Signals Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 | |
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121049T1 true CY1121049T1 (el) | 2019-12-11 |
Family
ID=46146394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100941T CY1121049T1 (el) | 2010-11-22 | 2018-09-12 | Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP2643468B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR20190060888A (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK2643468T3 (enExample) |
| ES (2) | ES2687415T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20192243T1 (hr) * | 2014-07-03 | 2020-03-06 | F. Hoffmann - La Roche Ag | Polipeptidni ekspresijski sustavi |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3635009A1 (en) | 2017-06-07 | 2020-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| TW201927825A (zh) * | 2017-11-30 | 2019-07-16 | 美商阿米庫斯醫療股份有限公司 | Cdkl5 表現變體和cdkl5 融合蛋白 |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| KR20210005154A (ko) | 2018-04-30 | 2021-01-13 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 유전자 요법 작제물 및 사용 방법 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| BR112021006829A2 (pt) | 2018-10-10 | 2021-07-20 | Amicus Therapeutics, Inc. | composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3120638A1 (en) * | 2018-12-19 | 2020-06-25 | Versameb Ag | Rna encoding a protein and a signal peptide with a hydrophobic amino-terminal end |
| CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| EP3980548A4 (en) * | 2019-04-30 | 2023-09-06 | The Trustees of The University of Pennsylvania | Compositions useful for treatment of pompe disease |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220259284A1 (en) | 2019-06-12 | 2022-08-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| EP4255500A1 (en) | 2020-12-01 | 2023-10-11 | The Trustees of The University of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| US20250034533A1 (en) | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4892132B2 (ja) * | 1998-11-24 | 2012-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送 |
| KR101348530B1 (ko) * | 2003-11-06 | 2014-02-14 | 다니스코 유에스 인크. | 프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현 |
| DK2007885T3 (da) * | 2006-04-11 | 2010-11-08 | Csl Behring Gmbh | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
-
2011
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9279007B2 (en) | 2016-03-08 |
| WO2012071422A3 (en) | 2012-08-02 |
| DK3461905T3 (da) | 2020-11-02 |
| CA2818689A1 (en) | 2012-05-31 |
| CA2818689C (en) | 2021-09-21 |
| RS57601B1 (sr) | 2018-11-30 |
| CN103328649A (zh) | 2013-09-25 |
| LT2643468T (lt) | 2018-09-10 |
| HUE039070T2 (hu) | 2018-12-28 |
| CN103328649B (zh) | 2016-06-22 |
| BR112013012671A2 (pt) | 2016-10-11 |
| KR20130121878A (ko) | 2013-11-06 |
| JP2014503198A (ja) | 2014-02-13 |
| EP3461905A1 (en) | 2019-04-03 |
| HRP20181315T1 (hr) | 2018-10-19 |
| KR20190060888A (ko) | 2019-06-03 |
| ES2687415T3 (es) | 2018-10-25 |
| EP3461905B1 (en) | 2020-08-05 |
| PT2643468T (pt) | 2018-10-11 |
| EP2643468A4 (en) | 2014-12-24 |
| DK2643468T3 (en) | 2018-09-24 |
| EP2643468A2 (en) | 2013-10-02 |
| SMT201800466T1 (it) | 2018-11-09 |
| WO2012071422A2 (en) | 2012-05-31 |
| SI2643468T1 (sl) | 2018-10-30 |
| PL2643468T3 (pl) | 2018-11-30 |
| US20140045216A1 (en) | 2014-02-13 |
| ES2829199T3 (es) | 2021-05-31 |
| EP2643468B1 (en) | 2018-07-04 |
| KR101984318B1 (ko) | 2019-05-31 |
| BR112013012671B1 (pt) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121049T1 (el) | Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων | |
| CY1122250T1 (el) | Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων | |
| CY1118576T1 (el) | Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23 | |
| JP2016501535A5 (enExample) | ||
| WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| EA201000357A1 (ru) | Антигенсвязывающие белки, связывающие с-fms человека | |
| MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| MY162752A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| JP2014221801A5 (enExample) | ||
| EA200700917A1 (ru) | Способ рефолдинга рекомбинантных антител | |
| JP2014503198A5 (enExample) | ||
| EA201171259A1 (ru) | Антительные гибридные белки с модифицированными сайтами связывания fcrn | |
| CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
| MX348071B (es) | Variantes de fc. | |
| HK1223303A1 (zh) | 凝血酶可裂解连接子 | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| IS8016A (is) | Prótín sem bindast viðtaka NOGO | |
| ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
| CY1117283T1 (el) | Σταθερα μονομερη και ολιγομερη αμυλοειδους βητα | |
| ATE474917T1 (de) | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide | |
| DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine | |
| ATE519784T1 (de) | An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz | |
| WO2009025300A1 (ja) | イミュノグロブリン結合能を有するペプチド |